NEJM Group, publisher of premier medical resources for research, education and professional practice, has announced that Jeffrey M. Drazen, Editor-in-Chief of the New England Journal of Medicine, will retire within the next year. To ensure a smooth transition, Drazen will continue to lead the Journal and NEJM Group until a successor is named.
Drazen has led the Journal through the publication of many landmark studies, including articles on early peanut consumption in infants at risk for allergy, practice-changing research of trastuzumab for HER2-positive breast cancer, and the earliest research on Ebola virus disease in West Africa. He also initiated many digital innovations on NEJM.org, such as Interactive Medical Cases, Quick Take videos, and Clinical Decisions articles.
Drazen also helped develop policies that led to more transparency in scientific publishing, including mandating clinical trial registration, requiring financial disclosures for authors, and making trial protocols and statistical analysis plans available when research is published. In his role as Editor-in-Chief of NEJM Group, he has overseen the development of NEJM Knowledge+, NEJM Catalyst, NEJM Resident 360, and NEJM 医学前沿.
Brought to you by Scope e-Knowledge Center, a trusted global partner for digital content transformation solutions - Abstracting & Indexing (A&I), Knowledge Modeling (Taxonomies, Thesauri and Ontologies), and Metadata Enrichment & Entity Extraction.
